Proposal for a sole supply arrangement for fentanyl patches in New Zealand

8 July 2013

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a new brand of fentanyl patches, Fentanyl Sandoz, under a sole supply arrangement with the local subsidiary of Swiss drug major Novartis (NOVN: VX).

This proposal arose from a request for proposals (RFP) issued by PHARMAC in which pharmaceutical companies were invited to compete to be the sole subsidized supplier of fentanyl patches, a strong pain killer also sold by US health care giant Johnson & Johnson (NYSE: JNJ) under the trade name Duragesic.

This proposal would provide savings to the Combined Pharmaceutical Budget and would result in a change in the funded brand of fentanyl patches Prices of the current Mylan fentanyl patch range from NZ$8.90 for 12.5mcg per hour to NZ$14.50 for 100mcg per hour, with the proposed price and subsidy for Fentanyl at these strengths being NZ$2.92 and
NZ$11.29. In summary:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK